文献速递高血压血脂与心血管预防

孤立性舒张期高血压降压治疗与心血管风险:个体患者数据荟萃分析

Blood pressure lowering in isolated diastolic hypertension and cardiovascular risk: an individual patient data meta-analysis.
PubMed 文献 · Eur Heart J · 2026-01-01

该研究汇总51项随机对照试验的个体患者数据,比较孤立性舒张期高血压(IDH,收缩压<130 mmHg且舒张压≥80 mmHg)患者与非IDH患者的降压疗效。中位随访4.2年,收缩压降低5 mmHg对主要心血管事件风险降低在IDH患者(HR 0.91;95%CI 0.82-1.01)与非IDH患者(HR 0.90;95%CI 0.89-0.92)间无显著交互作用(P=1.00)。

要点

  • IDH患者降压治疗的主要心血管事件相对风险降低与非IDH患者相似。
  • 基线收缩压<130 mmHg者中,舒张压降至<60 mmHg未见相对疗效减弱。
  • 不同心血管病史、年龄、既往用药及血压测量方法间相对疗效无显著差异。

核心结论

  • 无证据表明IDH患者接受药物降压治疗的疗效劣于或优于非IDH患者。
  • 在基线舒张压较低(直至<60 mmHg)的患者中,相对风险降低未减弱。

研究设计与样本

  • 汇总51项随机对照试验的个体患者数据,采用固定效应一阶段个体患者数据荟萃分析。
  • 共纳入358 325例参与者,其中15 845例(4.4%)患IDH。
  • IDH定义为收缩压<130 mmHg且舒张压≥80 mmHg。
  • 采用按试验分层的Cox比例风险模型分析数据。

主要发现

  • 中位随访4.2年,收缩压降低5 mmHg使主要心血管事件风险在IDH患者中HR 0.91(95%CI 0.82-1.01),非IDH患者中HR 0.90(95%CI 0.89-0.92),交互作用P=1.00。
  • 相对治疗效应在心血管病史、年龄、既往用药及血压测量方法间无统计学差异。

临床怎么用

  • 对IDH患者可考虑进行药物降压治疗,其相对获益与非IDH患者相似。
  • 基线舒张压较低者降压治疗仍可能带来相对风险降低,无需因舒张压偏低而排除治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Blood pressure (BP) lowering reduces cardiovascular disease (CVD) risk; however, the benefits of treating patients with normal systolic BP but elevated diastolic BP remain uncertain. METHODS: Data from 51 randomized controlled trials were pooled to compare BP-lowering effects in participants with and without isolated diastolic hypertension (IDH), defined as systolic BP < 130 mmHg and diastolic BP ≥ 80 mmHg. Treatment effects were stratified across baseline diastolic BP categories (range < 60 to ≥90 mmHg) among individuals with baseline systolic BP < 130 mmHg. Fixed-effect one-stage individual participant data meta-analyses were used, and Cox proportional hazard models, stratified by trial, were applied to analyse the data. RESULTS: Among 358 325 participants, 15 845 (4.4%) had IDH. At a median follow-up of 4.2 years, a 5 mmHg reduction in systolic BP reduced the risk of major cardiovascular events similarly in individuals with IDH [hazard ratio 0.91; 95% confidence interval (CI) 0.82-1.01] and those without IDH (hazard ratio 0.90; 95% CI 0.89-0.92; P for interaction = 1.00). Analyses by baseline diastolic BP showed no evidence of heterogeneity in treatment effects among individuals with baseline systolic BP < 130 mmHg (P for interaction = .26). Relative treatment effects were not statistically different by CVD history, age, prior medication use, and BP measurement methods. CONCLUSIONS: The study found no evidence to suggest that pharmacological BP-lowering therapy in individuals with IDH is less or more effective than in those without IDH. Relative risk reductions also did not diminish in those with lower diastolic BP, down to <60 mmHg at baseline. No meaningful differences across various clinical phenotypes were detected.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Bidel Z, Nazarzadeh M, Canoy D, et al. Blood pressure lowering in isolated diastolic hypertension and cardiovascular risk: an individual patient data meta-analysis. Eur Heart J. 2026. PMID: 41384429. doi:10.1093/eurheartj/ehaf962

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。